Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiangiogenic therapy through copper chelation.

Mary Sproull1, Martin Brechbiel, Kevin Camphausen

  • 1Imaging and Molecular Therapeutics Section, Radiation Oncology Branch, Radiation Oncology Sciences Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, B3B69, Bethesda, MD, USA.

Expert Opinion on Therapeutic Targets
|June 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236.

bioRxiv : the preprint server for biology·2026
Same author

CPSM: an R package for cancer patient survival risk model using transcriptomics and clinical data.

GigaScience·2026
Same author

Temporal Integration of Serum Proteomics, Metabolomics and MRI Tumor Volumetrics via Deep Learning Identifies Systemic Mediators of Glioblastoma Response to Chemoradiotherapy.

Research square·2026
Same author

A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma.

Practical radiation oncology·2026
Same author

Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.

medRxiv : the preprint server for health sciences·2026
Same author

Drug Repurposing in Glioblastoma Using a Machine Learning-Based Hybrid Feature Selection Approach.

International journal of molecular sciences·2025

Developing new antiangiogenic therapies requires cost-effective production and broad efficacy. Researchers are exploring copper-binding agents as a promising new class of broadly-acting antiangiogenic compounds.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Antiangiogenic therapies are crucial in cancer treatment, but clinical success depends on production economics and efficacy.
  • Recombinant protein production challenges, like with endostatin, highlight the need for cost-effective drug development.
  • The trend is shifting from highly selective to less selective antiangiogenic compounds for improved clinical outcomes.

Purpose of the Study:

  • To evaluate new classes of broadly-acting antiangiogenic agents that target copper.
  • To explore the potential of copper-binding compounds in inhibiting angiogenesis.
  • To review historical and emerging applications of anticopper therapy.

Main Methods:

  • Review of existing literature on antiangiogenic therapies and compound development.

Related Experiment Videos

  • Analysis of preclinical models comparing selective and less selective antiangiogenic agents.
  • Examination of molecular techniques to identify copper-utilizing enzymes in angiogenesis.

    • Main Results:

    • Production cost and ease are critical factors alongside clinical efficacy for antiangiogenic drugs.
    • Less selective compounds show greater promise in preclinical models compared to highly selective ones.
    • Copper is identified as a significant target for novel antiangiogenic strategies.

    Conclusions:

    • Future antiangiogenic therapies must balance efficacy with production feasibility.
    • Broadly-acting agents, particularly those targeting copper, represent a promising avenue for cancer treatment.
    • Further research into copper-binding compounds could lead to more effective antiangiogenic drugs.